Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hedin Belgien Bil AB acquires Rudi Vertommen NV.

Gothenburg, August 22nd 2019 I.A. Hedin Bil AB has through its subsidiary, Hedin Belgien Bil AB, entered an agreement to acquire Rudi Vertommen NV. The deal includes a full-service dealership for PC and LCV Mercedes-Benz. The dealership operates under the brand Vertommen and is situated in Boortmeerbeek.- In 2018, Hedin Bil successfully took over the operations of 12 Mercedes-Benz dealerships in and around Ghent and Antwerp. The acquisition of Rudi Vertommen NV. complements our existing business in a strategic way and I look forward to further expand our offer in the Belgian market”,

CONTEMPLATING THE ISSUANCE OF SENIOR UNSECURED BONDS

Bonheur ASA is contemplating the issuance of NOK 700 million in a 5 year NOK denominated floating rate senior unsecured bond. DNB Markets and SpareBank1 Markets have been retained as joint lead managers of the potential bond issue. For further information, please contact: Øyvind B. Kristiansen, Fred. Olsen & Co., +47 90 01 05 29 or oyvindk@fredolsen.com or Haakon Magne Ore, Fred. Olsen & Co., +47 92 02 75 10 or hmore@fredolsen.com

ChromoGenics receives an order from Hungary to a value of SEK 450.000

ChromoGenics has received a High-Performance Glass order for a privately owned exclusive villa property. The property is under production and is located overlooking the Donau River outside Budapest in Hungary."We are very pleased that the property owner has noticed ChromoGenics and also prioritized the performance of the glass. There will now be no needs to install external sun protection to cope with the comfort during all four seasons," says CEO Jerker Lundgren.

Senzime’s Interim report January – June 2019

Press release: Uppsala, August 22, 2019. Senzime AB’s (publ) Interim report for January – June 2019 is now available on the company’s webbsite www.senzime.com. Financial information second quarter 2019 ·  Net sales amounts to KSEK 1 218 (381) ·  Income after financial items amounts to KSEK -9,153 (-5,543) ·  Earnings per share before dilution amounts to SEK -0.17 (-0.12) We are now halfway into the year and work on the launch of TetraGraph continues at an intensive pace. A breakthrough order of 50 pcs. TetraGraph systems from South Korea in May were quickly followed

The usefulness of Bioservo Technologies’ patented and award-winning SEM technology demonstrated in scientific study

A recently published article in the scientific journal PLOS ONE demonstrates that Bioservo Technologies’ wearable soft-robotic glove may counter hand function decline associated with ageing.In the article “Home rehabilitation supported by a wearable soft-robotic device for improving hand function in older adults: A pilot randomized controlled trial”* research results are reported demonstrating that support of the soft-robotic glove either as an assistive device or as a training tool may be a promising way to counter hand function decline associated with ageing. The randomized controlled

Borr Drilling Limited – Notice of Annual General Meeting 2019

A copy of the Notice of Annual General Meeting and Form of Proxy, and associated information including the Company’s Annual Report can be found on the Company’s website at http://www.borrdrilling.com and attached to this press release. The notice and associated information will also be distributed to shareholders by normal distribution methods. Hamilton, Bermuda22 August 2019 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Borr Drilling AGM Notice 2019 with byelaws 

Borr Drilling Limited – Paal Kibsgaard recommended as new Chairman of the Board

The Board of Borr Drilling has based on the unanimous decision from the nomination committee, decided to recommend Paal Kibsgaard as new Chairman of the Board of Borr Drilling. The election will take place at the annual general meeting to be held on September 27, 2019. Mr. Kibsgaard has through his 27 years of experience, a deep knowledge of the oil and gas industry. He has held a variety of global senior management positions at Schlumberger Limited, including Chairman and CEO, COO, President of the Reservoir Characterization Group, VP of Engineering, Manufacturing and Sustaining, and VP

Interim report quarter 2 -  Continued Efemia market expansion with Germany in sight

SECOND QUARTER (April - June 2019) · The company’s sales amounted to 101 (0) KSEK. · Work capitalised by the company for its own use amounted to 0 (187) KSEK. · Operating costs amounted to 3,243 (2,043) KSEK. · Result after tax amounted to -3,143 (-1,857) KSEK. · Result per share amounted to -0.30 (-0.19) SEK. CEO Karin Bryder summarizes the quarter  During the second quarter of 2019, we continued to focus on establishing and marketing Invent Medic’s first product Efemia Bladder Support in Sweden, the Nordic region and Europe. The marketing activities are targeting

Interim Report January – June 2019

Significant events during the second quarter 2019 · SRK Consulting is retained to perform a scoping study of the potential in the Väsman field. · Exploration permit for Ludvikafältet # 1 is granted by the Swedish Mining Inspectorate. · Golder Associates informed that the feasibility study will be delayed by approx. one month. · A short-term credit facility amounting to SEK 10 m was granted by the two largest owners. · Timo Lindborg was elected member of the board at the AGM. Second quarter, 1 April – 30 June 2019 · Income amounted to SEK 0 million (0) · Earnings

SEMCON IN NEW DIGITAL TWINS PARTNERSHIP

Creating virtual copies of physical products offers great opportunities for future product development. Semcon is now entering a new partnership with EDRMedeso, which develops and sells software for design, development and simulation.“We are very pleased that EDRMedeso is becoming one of our partners in digital twin development. Together with our extensive expertise in product development, we can offer digital solutions at the very cutting edge of technology with a clear user focus,” says Markus Granlund, CEO of Semcon. When a virtual copy is created and can be connected with a physical

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2019 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter  · In May 2019, Cantargia AB and Patheon Biologics B.V. (a part of ThermoFischer Scientific) signed an agreement on future production of the CAN04 antibody.  · In May 2019, Cantargia announced new preclinical results showing positive effects when the CAN04 antibody is combined with various platinum-based chemotherapies. · New phase I clinical data on Cantargia´s

Ericsson announces changes to the Executive Team

· Fadi Pharaon is appointed Senior Vice President, and Head of Market Area Middle East & Africa, effective September 1, 2019 · Member of Ericsson's Executive Team, reporting to CEOEffective September 1, 2019, Fadi Pharaon is appointed Senior Vice President and Head of Market Area Middle East & Africa at Ericsson (NASDAQ: ERIC), and member of Ericsson’s Executive Team, reporting to the CEO. Fadi Pharaon currently holds the position as Vice President, Networks & Managed Services within Ericsson’s Market Area Europe & Latin America. Börje Ekholm, President and CEO of Ericsson, says: "

ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.CEO Steen Klysner comments “The sales and marketing activities initiated in 2018 are beginning to show significant results. Compared to H1 2018 ExpreS[2]ion is able to present a revenue growth of 34 %. During H1 2019 we also witnessed a large and continuous growth in our potential revenue pipeline. We expect to

Interim Report 2, 2019 - Record-breaking quarter strengthens Speqta's preparations for further expansion

Speqta AB (plc) Interim Report for quarter 2, 2019 has now been made public and is available at https://speqta.com/investors/financial-reports Significant events during the period  - Net sales for the second quarter amounted to KSEK 25,633 (13,465), which corresponds to a 90% growth.- Adjusted EBITDA result increased by 115% and amounted to KSEK 5,558 (2,589), which corresponds to an adjusted EBITDA-margin of 22% (19).- Cash flow from operations between April and June 2019 increased and amounted to KSEK 3,477 (244).- The segment Shopping increased sales by 151% to KSEK 20,

Stillfront lists 500 MSEK 5-year senior unsecured bonds on the Frankfurt Stock Exchange Open Market

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL Pressrelease Stockholm 2019-08-22Stillfront Group AB (publ) (“Stillfront” or the “Company”) has successfully listed its MSEK 500 senior unsecured bonds due 2024 (the “Bonds”) on the Open Market of the Frankfurt Stock Exchange (Freiverkehr). The Company is pleased to announce that the Bonds have

Dignitana AB Publishes Q2 2019 Interim Report

Financial highlights ·  Total revenue for the Group amounted to 12,002 TSEK, 1,275 KUSD which is an increase of 33 percent over the same period 2018. ·  Year to date revenue for the Group was 22,109 TSEK, 2,350 KUSD, an increase of 47 percent over the same period 2018. Business highlights   ·  FDA clearance of the next generation DigniCap Delta June 2019.   ·  First European installation of DigniCap Delta at Gemelli University Hospital in Rome, Italy, in May 2019.   ·  Contracts were signed for 19 locations in the United States, bringing the total number of signed U.S.

Half-Year Report 1 January 2019 – 30 June 2019

Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes the Half-Year Report for the period 1 January – 30 June 2019. The Half-Year Report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.Reporting period April 2019 – June 2019 · Net sales amounted to DKK 0 (0). · Operating profit was -4.851m DKK (-2.366). · Cash and bank assets amounted to 3.160 m DKK (327). · Result per share was DKK -0.33 (-0.23). Reporting period January 2019 – June 2019 · Net sales amounted to DKK 0 (0). · Operating profit

InCoax Networks AB’s Interim Report, January – June 2019

Several evaluation studies were initiated and the first commercial installations of In:xtnd™ in Europe are under way.Financial performance April–June 2019 · Net sales amounted to SEK 1,108,187 (525,851), which is equivalent to an increase of 111% compared with the corresponding period in the preceding year. · The company posted an operating loss of SEK –18,654,944 (–11,647,705), a reduction driven primarily by organizational growth. · The loss after tax was SEK –18,695,898 (–11,701,346), corresponding to earnings per share of SEK –1.51 (–1.75). · Cash flow including financing

NOTICE OF EXTRAORDINARY SHAREHOLDERS’ MEETING IN INCOAX NETWORKS AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of InCoax Network AB, Reg. No. 556794-1363, are hereby invited to attend the extraordinary shareholders’ meeting to be held at the company’s premises at Utmarksvägen 4 in Gävle, on Monday 9 September 2019, at 1.00 p.m.Right to participate and notification Shareholders wishing to participate in the meeting must: · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Tuesday 3

Moberg Pharma’s Year-end report to be published on August 29 - Invitation to teleconference

STOCKHOLM, August 22th, 2019 - On August 29th 2019, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report 2019. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English. Date:             August 29th, 2019Time:             3:00 pm (CET) To participate in the conference, please dial in on any number below before the start of the call: SE:

Flexion Mobile Plc - Q1 Report 30 June 2019

Flexion delivers a solid quarter and continues to expand its portfolio of games. During the first quarter of the new financial year, IAP (In-App Purchase) revenue increased by 39% to GBP 1.9m compared to the same period last year and total annual revenue increased by 35% to GBP 1.9m. The Company signed its second biggest top-tier title and one mid-tier game while also launching three of its signed top-tier games.April 2019 to June 2019 performance · IAP (In App Purchase) revenue increased by 39% to GBP 1.9m (GBP 1.3m*) · Total revenue increased by 35% to GBP 1.9m (GBP 1.4m) ·

AstraZeneca agrees to buy US FDA Priority Review

22 August 2019 07:00 BST AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval. The transaction is subject to clearance under the Hart-Scott

Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease

22 August 2019 07:00 BST Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease China is the first country to approve roxadustat for all chronic kidney disease patients with anaemia AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients. This approval, granted by the National

There are no items matching the current filter
There are no more items matching the current filter
Back to top